Media coverage
85
Media coverage
Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Morningstar.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255118314&p=1gw&v=1&x=PSnxt_TuA3b8YyyIQkeGyg Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Street Insider Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255013000&p=1gw&v=1&x=dJdnLhav7d7MoclC3_L2xg Persons Ronald Hoffman Title Protagonist Therapeutics (PTGX) Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Street Insider Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255049701&p=1gw&v=1&x=JFA3pZlPFc2FoTv_dEIVdQ Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet BioSpace Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255439837&p=1gw&v=1&x=ijgJaeWEe2TxZW1WAhhqvQ Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Le Lezard.com Country/Territory Canada Date 15/03/23 URL ct.moreover.com/?a=50255071078&p=1gw&v=1&x=nsLaouLyO3V1qpFrVbNyGw Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Yahoo! Finance Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255076314&p=1gw&v=1&x=PadQQ2mZRrvRgbTLoiZkXg Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet TD Ameritrade Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255042828&p=1gw&v=1&x=4Qgfq4HVr9QJfqIahE7S3g Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Stockwatch Country/Territory Canada Date 15/03/23 URL ct.moreover.com/?a=50255059317&p=1gw&v=1&x=-QD-O2kJZNbzGWwz-6C1gA Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Big Country Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255471628&p=1gw&v=1&x=pckTb425929iE-fjeDUopw Persons Ronald Hoffman Title Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Market News Publishing Country/Territory United States Date 15/03/23 Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Accesswire Country/Territory Canada Date 15/03/23 URL ct.moreover.com/?a=50255042036&p=1gw&v=1&x=ZpS4nO3ogGyrgWV4LW3qpQ Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant ... Media name/outlet PR inside Country/Territory Austria Date 15/03/23 URL ct.moreover.com/?a=50255009813&p=1gw&v=1&x=YYlwymwuekHFEZkG5soccw Persons Ronald Hoffman Title Protagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet FinanzNachrichten.de Country/Territory Germany Date 15/03/23 URL ct.moreover.com/?a=50255060157&p=1gw&v=1&x=4OzD-IEJKzGSvIyoD5w9IA Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WCBD Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255205682&p=1gw&v=1&x=ueE_OXb-6svFpC6Ltrc2Rg Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KSN Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255210051&p=1gw&v=1&x=iKXaSXvNc7eUD_0TWfzD9A Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet OurQuadCities.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255215312&p=1gw&v=1&x=TYZ8eEzmzUh-DVzyuoTUqA Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KNWA Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255220655&p=1gw&v=1&x=Z1C-W-WRNDdo4DD4bJ47Mg Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KGET Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255224446&p=1gw&v=1&x=6Ifg3GCNUFtVWDDEKOseuA Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WeAreGreenBay.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255228120&p=1gw&v=1&x=cm8X7KakHNaf6wYguG_EoQ Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WFXRTV.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255230289&p=1gw&v=1&x=sxWGaqqfoRqVgbRAyUBbXw Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KXNet.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255234906&p=1gw&v=1&x=vlj56XoNvUrJe1ZE9bkY5A Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WBOY Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255238528&p=1gw&v=1&x=_0hTBQk6TdXZj1cn8y52Jw Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WYTV News Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255238656&p=1gw&v=1&x=KYvUgTxAtkS-ssk311wvZg Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WBTW News13 Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255240968&p=1gw&v=1&x=061TWRJhStfO1nNCWoZVvg Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet ABC 4 Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255246478&p=1gw&v=1&x=sFQ9_g1y-9CiPFuANMtSdQ Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WSPA.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255255884&p=1gw&v=1&x=vap51yMmc0QB4HyNLFQmrQ Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WIProud.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255261527&p=1gw&v=1&x=58FRQGifLCUbma2VmSQ-TQ Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WYOU Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255264518&p=1gw&v=1&x=IrpTZoaezfj48AJJEW5K-A Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WETM 18 Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255281041&p=1gw&v=1&x=EdqaYte5JJUvcHjCh-3e4w Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WOWK Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255282397&p=1gw&v=1&x=SzIOFx2NamlpQRdqTGXB-w Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KTSM.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255289601&p=1gw&v=1&x=6z0rB3UUF5StPyxNlRIyeA Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Wavy Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255299270&p=1gw&v=1&x=_aCEbx_8v_MFCsh9nOdfdA Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet My Champlain Valley Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255311652&p=1gw&v=1&x=XWodlb3nBSdKbYP5RUMSdw Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Binghamton Homepage Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255314506&p=1gw&v=1&x=xpTyModKYZGCuZf2IodUrg Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet LocalSRY.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255335989&p=1gw&v=1&x=1feRF6-IiugTv2OPDLHb1A Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet FOX 59 Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255336569&p=1gw&v=1&x=AIwJ0df460UHmV3c5V5aSA Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KSNT TV Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255338647&p=1gw&v=1&x=TTu116SDA0zP7J_xmmLSJA Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WSAV Country/Territory Georgia Date 15/03/23 URL ct.moreover.com/?a=50255355724&p=1gw&v=1&x=NDayJH1j9Wtmgs4lB5Uwnw Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WDTN Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255360742&p=1gw&v=1&x=udCVzc8uWSJ4JCBsQWl55g Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Fox 4 WDAF TV Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255363370&p=1gw&v=1&x=1Go_O6NA4iHyHCpHKEDZsA Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Valleycentral.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255374961&p=1gw&v=1&x=PcQdQfRkcWwGqW3AgjKoxg Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WCIA.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255380017&p=1gw&v=1&x=NIWI_57uCFyFCB56BJRuAg Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KODE TV Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255383837&p=1gw&v=1&x=x_jXX1josh3XGA1BtB8aWA Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WTVW FOX 7 Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255383878&p=1gw&v=1&x=TfpZt01Kg9uleNFkeaR5pg Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Myarklamiss.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255385542&p=1gw&v=1&x=Qnm0f-1ZHF-OBkcySY6BPw Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WWLP.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255386543&p=1gw&v=1&x=6oXuR9yt04P2BkNPoekdfA Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet 8 News Now Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255392421&p=1gw&v=1&x=nlGKn4f0dujnUbA5X6uJwQ Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WJTV.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255393540&p=1gw&v=1&x=tYEwL7mmK3p9i0Ys0FFCKA Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Fox40 KTXL Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255402997&p=1gw&v=1&x=UBtrkbwXO4NS0nbbWe5sTw Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KELOLAND TV Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255403195&p=1gw&v=1&x=0bmcUtwKaafD0u2RoEqQpg Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet FOX21News.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255412465&p=1gw&v=1&x=nuTX58SJUeokq1Nhjy8OdQ Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet YourCentralValley.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255412619&p=1gw&v=1&x=K4igAWKBLHeew-BaUAhKYw Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WJET Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255412826&p=1gw&v=1&x=J4hYqv2jin-KjtUBVLqSnA Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WJBF-TV Country/Territory Georgia Date 15/03/23 URL ct.moreover.com/?a=50255418526&p=1gw&v=1&x=pSPiW4L5lng4Gex1WblsQA Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Kark.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255419836&p=1gw&v=1&x=6X-rM1v-VhRnY4BQZLfK5g Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet ABC 27 Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255420991&p=1gw&v=1&x=84hXplYSjRLekpbtRL84-w Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WYZZ-TV Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255431408&p=1gw&v=1&x=dwERxvuT79UY-4tB2LJTIQ Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet CW33 NewsFix Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255440768&p=1gw&v=1&x=cqYuc6wN61VfLcbpiaTdTw Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet CNYHomepage.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255442289&p=1gw&v=1&x=OsvwSBBPQXfXhGx2J1pbVA Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WIAT TV Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255443097&p=1gw&v=1&x=uGUoyNIGRt9yer8yQ0IHmg Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WATE Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255446812&p=1gw&v=1&x=VzWJXCfJbIpyiXavyFFU_A Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WVNS Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255447238&p=1gw&v=1&x=G17dYvmOJSsuYYMGypTqlw Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet MyStateLine.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255449279&p=1gw&v=1&x=U0tml9HLluu1bNb3B-UQMg Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WKRG Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255449874&p=1gw&v=1&x=cteZF0iU_lsSZBjXx2YuiQ Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet OzarksFirst.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255451166&p=1gw&v=1&x=tB90lCWCp6hFlJ3QaYerlw Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WTRF Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255451979&p=1gw&v=1&x=aINP82IA5iBZFlskFCffzw Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet INFORMNNY.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255452299&p=1gw&v=1&x=BDg-0l8s8DwVO0n9sOb_Qw Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WLNS Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255453094&p=1gw&v=1&x=OX30opwoLSrRVhUN_CfW_w Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet MyHighPlains.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255457587&p=1gw&v=1&x=39aYssjw6Ja7Q6N7ntXKwA Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WRBL-TV Country/Territory Georgia Date 15/03/23 URL ct.moreover.com/?a=50255458193&p=1gw&v=1&x=Fx9o4lBFqf9uvmsjKhYMnw Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KRQE Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255459577&p=1gw&v=1&x=jwrxGles4uuNnZ6bDk1q-Q Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet CBS4Indy Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255460393&p=1gw&v=1&x=79dmvsj1NrPYtxGxqIthjA Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet ConchoValleyHomepage.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255462263&p=1gw&v=1&x=MgLgnIDADF6Y1kg0zotJnw Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WNCT Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255465670&p=1gw&v=1&x=OgFI8By59VlZVYptKoeIaA Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WPRI Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255474107&p=1gw&v=1&x=urkdR1LFShVBLyLrIIbJGg Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WTAJ-TV Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255487575&p=1gw&v=1&x=ENYOBqda6JJ7qTd6PzcU6A Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WHNT-TV Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255487655&p=1gw&v=1&x=UrdgJckT7eArymzpFQZKvw Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Texomashomepage.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255488967&p=1gw&v=1&x=4v24pF90o48EaGQQVECcOw Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KLFY Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255503315&p=1gw&v=1&x=uCzDT28DySVOiXmIWxfeOA Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WKRN Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255515599&p=1gw&v=1&x=SD8Pk3yxjT91sDO3M7ucGQ Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Rochesterfirst.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255527392&p=1gw&v=1&x=SLTpUS3XZ02aIoHF2OwfVg Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WRIC TV Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255548888&p=1gw&v=1&x=ZHmTYevu9Y2lsNwhzArplQ Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WesternSlopeNow.com Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255570425&p=1gw&v=1&x=eR-EfS3kxvQy7rYOiSwa4w Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KHON 2 Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255630649&p=1gw&v=1&x=_HoaXY_TTW1UlE23OCF6Cg Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WNTZ Country/Territory United States Date 15/03/23 URL ct.moreover.com/?a=50255642112&p=1gw&v=1&x=R0w6peelH068LHxYDqKgZA Persons Ronald Hoffman